Artivion Inc stock reaches 52-week high at 32.38 USD

Published 10/07/2025, 14:58
Artivion Inc stock reaches 52-week high at 32.38 USD

Artivion Inc’s stock has reached a 52-week high, hitting 32.38 USD, marking a significant milestone for the $1.51 billion market cap company. According to InvestingPro analysis, the stock appears to be trading above its Fair Value, with analysts setting price targets between $30-35. This achievement reflects a positive trend over the past year, during which the stock has experienced a notable increase of 23.65%. The rise to this 52-week high underscores the market’s confidence in Artivion Inc’s performance and potential, supported by strong fundamentals including a healthy current ratio of 5.53 and revenue growth of 5.94%. InvestingPro subscribers can access 8 additional key insights and a comprehensive Pro Research Report about Artivion’s outlook and valuation metrics.

In other recent news, Artivion Inc. reported first-quarter earnings for 2025 that exceeded expectations, with sales reaching $99 million against a consensus estimate of $95 million. This increase was driven by the successful early launch of the AMDS product, contributing to a 19% year-over-year growth in the aortic stent graft business. Additionally, the On-X platform saw an 11% increase, recovering from previous supply issues. Meanwhile, Artivion announced agreements to repurchase approximately $95 million of its Convertible Senior Notes due 2025, exchanging them for common stock. This move is part of the company’s strategy to manage its debt effectively. Shareholders also approved executive pay and additional equity funding during the 2025 Annual Meeting. Canaccord Genuity initiated coverage on Artivion with a buy rating, citing strategic investments in aortic arch repair. JMP Securities and Stifel maintained their favorable ratings on the stock, highlighting Artivion’s growth prospects and product launches.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.